CN108524748A - Treat the Chinese medicine composition that myasthenia gravis merges fash - Google Patents
Treat the Chinese medicine composition that myasthenia gravis merges fash Download PDFInfo
- Publication number
- CN108524748A CN108524748A CN201810769795.0A CN201810769795A CN108524748A CN 108524748 A CN108524748 A CN 108524748A CN 201810769795 A CN201810769795 A CN 201810769795A CN 108524748 A CN108524748 A CN 108524748A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- chinese
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Chinese prescriptions treated myasthenia gravis and merge fash, which be prepared for bulk pharmaceutical chemicals by 10 100 parts of Radix Astragali, 10 30 parts of Radix Codonopsis, 10 24 parts of Rhizoma Atractylodis Macrocephalae, 5 10 parts of radix bupleuri, 5 10 parts of cimicifugae foetidae, 5 10 parts of Radix Angelicae Sinensis, 36 parts of Radix Glycyrrhizae, 36 parts of dried orange peel, 5 10 parts of matrimony vine, 9 12 parts of dogwood fruit, 10 24 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 6 15 parts of mulberries, 5 15 parts of the root of straight ladybell, 5 15 parts of waxgourd peel, 5 10 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, 10 20 parts of radix pseudostellariae.The Chinese medicine composition of the present invention is using Chinese medicine as bulk pharmaceutical chemicals, and without any toxicity and side effects, raw material sources are abundant, compatibility is reasonable, preparation process is simple, of low cost, good effect, it is quick, a variety of dosage forms can be prepared into, meet the needs of different patients, are easy to clinically promote.
Description
Technical field
The invention belongs to the field of Chinese medicines, are related to a kind of Chinese medicine composition treated myasthenia gravis and merge fash.
Background technology
The disease for the 0.65%-1% that the World Health Organization (WHO) accounts for number of patients population calls orphan disease.
Orphan disease epidemic data has certain reference significance for the formulation for developing Orphan drug and health policy.Severe flesh
Inability belongs to rare disease, and incidence is different according to age, gender and race.Myasthenia gravis ((myasthenia
Gravis, MG) it is a kind of neuromuscular junction transfer function generation obstacle, mainly involve postsynaptic membrane acetylcholinergic receptor
(AchR), it is oneself participated in by one kind, cellular immunity dependence and complement that acetylcholine receptor antibody (AchRab) mediates
Body immunity disease.
MG illness rates at home and incidence give exact number, root currently without the investigation of large-scale epidemiology
It is recorded according to domestic textbook：Some up to 33-110 people/100,000, also down to 4 people/100,000,0.5-5 people/100,000, these are counted some
Word mostly quotes foreign data, cannot represent domestic actual diseased situation.One epidemiological survey report carried out in Hunan
It accuses and shows that the illness rate of MG is 10 people/100,000, annual morbidity 2.5 people/100,000.If being population with 1,400,000,000, me is substantially estimated
State may have 140,000 Patients With Myasthenia Gravis.
In the observation to MG incidence over the years and illness rate situation of change, there is research by analyzing 1996 to 2013
Number it has been found that age-sex's adjusted prevalence of MG rises to 26.3/10 ten thousand in 2013 from 16.3/10 ten thousand in 1996, mark
Change incidence relatively to stablize, it is 2.3/10 ten thousand that 1996, which are 2.7/10 ten thousand, 2013, as a result prompts the MG survival of patients times longer,
I.e. the course of disease is longer, may be due to the raising of health care technology, but that thus brings can not be ignored the consumption of medical resource.Have
Studies have shown that as selection is not treated, the MG patient of 20-30% can be dead in 10 years, most of if suitably treated
Patient can normally survive.
The pathogenesis of myasthenia gravis
It may be autoimmune disease that nineteen sixty Britain Simpsom and Nastuk etc., which are put forward for the first time MG, 1973
Fambrough etc. is utilized can be with the a- silver rings of acetylcholine receptor (acetylcholine receptors, AchR) single combination
MG models are made in ophiotoxin, and new opportunity is provided to disclose MG pathogenesis.AchR is present in the neuromuscular junction postsynaptic
Film, closely related with the function switching signal of neuromuscular junction, there are many store second phthalein choline in presynaptic membrane
The vesica of (acetylcholine, ACh), postsynaptic membrane include AchR, and AChR causes muscle action potential after being combined with ACh, if
Internal autoantibody acetylcholine receptor antibody (acetylcholine receptor antibody, AchRab) excessively high, AChR
It is destroyed, quantity is reduced, and is prevented end plate potential from effectively expanding as muscle fibre action potential, is then caused muscular contraction force to weaken
River.Immunologic balance destruction plays a crucial role in Pathogenesis of Myasthenia Gravis, and panimmunity correlative factor is participated.T drenches
Bar cell subsets dysfunction is related with the generation of MG patient's bodies AchRab, and T adjusts cell and MG patient's bodies are main exempts from
Epidemic disease controlling mechanism is related, and when the function or abnormal proportion of T cell subgroup, if Th2 increases, suppressor T lymphocyte is reduced, and can be made
At the activation of autoreactivity B cell, autoantibody is generated.There is peripheral blood CD4+ cells helper T lymphocyte to be changed into effect
The effects that answering cell and bone-marrow-derived lymphocyte to generate antibody, can induce and the effect of auxiliary cell and humoral immunity, if CD4+ cells
Abnormal increase causes bone-marrow-derived lymphocyte hyperfunction, a large amount of autoantibodies and immunoglobulin to generate, then may lead to severe flesh
Powerless generation.CD8+ cells, which have, to be inhibited T lymphocyte activities and inhibits B cell to generate antibody and generate the works such as cell toxicant
With playing the role of inhibiting cell and humoral immunity.By detecting t lymphocyte subset type, CD4+/CD8+ ratios can reflect certain
The state of a little diseases, as a kind of means of observation disease.
Conventional treatments
Modern medicine mostly uses symptomatic treatment, and the cruel enzyme drug of cholinolytic can obviously improve symptom, but action time is short, only
Drug is controlled for symptom, to disease itself without obvious effect, common adverse effect includes perspiration, abdominal pain, diarrhea, muscle beat, pupil
Very then there is the symptom that excitement, delirium etc. diffuse cerebral cortex damage in hole diminution etc..Hormone medicine, is immunized immunosuppressor
Though globulin etc. has certain curative effect, erious adverse reaction, it is difficult to remove rapidly, easily be recurred after drug withdrawal, as hormone medicine is common
There is muscle inability, pain, atrophy etc. in moon shaped face, hemorrhage of digestive tract, long-term use.Ring phosphorus phthalein amine prolonged application can cause white thin
Born of the same parents are reduced.Plasma exchange method and immuno absorbence have clear short term efficacy, but maintain curative effect time short, and have certain danger
Property, it is only suitable for treatment when patient with severe symptoms's rescue；Thymectomy is to treat the effective ways of MG, especially merges thymic hyperplasia
With the MG patient of thymoma, but most of patients cannot directly improve symptom after cutting off thymus gland, and most of patient is still after operation
Need long-term drug therapy.
Clinically the therapeutic purposes of MG are now to control symptom, the generation of Myasthenia Gravis Crisis is prevented, improves life
Bioplasm amount improves patient immune function, and gradually decreases Western medicine dosage after controlling symptom, also to prevent symptom after being discontinued multiple
Hair.From the point of view of existing research, Chinese medicine measure is improving the clinical symptoms of patient, immune function, the west for reducing patient
Medicine usage amount has potential effect.
Invention content
For overcome the deficiencies in the prior art, it is prepared using natural material medicine the purpose of the present invention is to provide a kind of
Treatment with deficiency of both qi and yin, yin asthenia generating intrinsic heat, failure of skin and muscle to be nourished myasthenia gravis merge fash Chinese prescription.In the present invention
Medicine prescription is without any toxicity and side effects, quick, good effect, compatibility is reasonable, preparation process is simple, of low cost, is suitable for clinically
It promotes the use of.
To achieve the goals above, present invention employs following technical solutions：
According to an aspect of the present invention, the present invention provides a kind of Chinese medicine groups treated myasthenia gravis and merge fash
Side, the Chinese prescription includes the bulk pharmaceutical chemicals of following parts by weight：Radix Astragali (Astragalus membranaceus (Fisch.)
Bge.) 10-100 parts, 10-30 parts of Radix Codonopsis (RADIX CODONOPSIS), Rhizoma Atractylodis Macrocephalae (Atractylodes macrocephala)
10-24 parts, 5-10 parts of radix bupleuri (Radix Bupleuri), 5-10 parts of cimicifugae foetidae (RHIZOMA CIMICIFUGAE), Radix Angelicae Sinensis
(Angelica sinensis (Oliv.) Diels.) 5-10 parts, Radix Glycyrrhizae (Glycyrriza Uralensis
Fisch.G.Glabra L.) 3-6 parts, 3-6 parts of dried orange peel (PERICARPIUM), 5-10 parts of matrimony vine (Fructus Lycii), mountain cornel
9-12 parts of meat (Macrocarpium officinalis), 10-24 parts of RADIX POLYGONI MULTIFLORI PREPARATA (Polygonum multiflorum), mulberries
6-15 parts of (Fructus Mori), 5-15 parts of the root of straight ladybell (Adenophora coelestis), waxgourd peel (Exocarpium
Benincase) 5-15 parts, Sagina subulata (Phyllanthus urinaria Linn) 5-10 parts, rhizoma anemarrhenae (Rhizoma
Anemarrhenae) 10 parts, 10-20 parts of radix pseudostellariae (Radix Pseudostellariae).
Preferably, the Chinese prescription includes the bulk pharmaceutical chemicals of following parts by weight：50 parts of Radix Astragali, 20 parts of Radix Codonopsis, 15 parts of Rhizoma Atractylodis Macrocephalae,
8 parts of radix bupleuri, 8 parts of cimicifugae foetidae, 8 parts of Radix Angelicae Sinensis, 5 parts of Radix Glycyrrhizae, 5 parts of dried orange peel, 8 parts of matrimony vine, 10 parts of dogwood fruit, 15 parts of RADIX POLYGONI MULTIFLORI PREPARATA, mulberries 10
Part, 10 parts of the root of straight ladybell, 10 parts of waxgourd peel, 8 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, 15 parts of radix pseudostellariae.
Composition described above is can proportionally to increase or reduce in production, such as mass produce as proportioning by weight
Can by kilogram as unit of, or as unit of ton, small-scale production can be as unit of milligram, and weight can increase or subtract
It is small, but the constant rate of the raw medicinal herbs weight proportion between each composition.
According to another aspect of the present invention, the present invention provides a kind of Chinese medicines treated myasthenia gravis and merge fash
Liquid, the herb liquid are obtained by the method that water decocts by foregoing Chinese prescription.
Further, the preparation method of the herb liquid is as follows：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 5-10 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice；
Further, the preparation method of the herb liquid is as follows：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 5-10 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice；It boils medicine, adds for the first time
Enter the 2/3 of total Water, intense fire is suddenly fried boiling rise after change and be cooked by slow fire 20-25 minutes, pour out Chinese medicine concoction；Remaining water is added in the remaining dregs of a decoction
Amount is boiled medicine for the second time, and same intense fire is suddenly decocted, and is cooked by slow fire after boiling 15-20 minutes, is poured out Chinese medicine concoction；
(3) hybrid filtering：It Chinese medicine concoction will be uniformly mixed twice, it is after cooling precipitation, upper layer liquid is medical by two layers
Gauze or the filtering of non-woven fabrics filter bag, obtain the herb liquid.
According to a further aspect of the invention, the present invention also provides a kind of drugs treated myasthenia gravis and merge fash
Preparation, the pharmaceutical preparation are that common auxiliary material in pharmacy will be added after foregoing Chinese medicinal liquid concentrating to be prepared.
Common auxiliary material includes but not limited to pharmaceutically acceptable carrier, dilution in pharmacy for use in the present invention
Agent, excipient, adjuvant, buffer, pH adjusting agent, preservative, antioxidant, bacteriostatic agent, stabilizer, suspending agent, solubilizer, table
Face activating agent (such as wetting agent), colorant and isotonic (isotonicizing) solute of cause.Carrier appropriate, diluent, figuration
Agent etc. can be found in standard pharmaceutical books.See, e.g. medicated premix handbook (Handbookof
Pharmaceutical Additives), the second edition (editor M.Ash and I.Ash), 2001 (SynapseInformation
Resources, Inc., Endicott, New York, USA)；Remington ' sPharmaceutical Science, the 18th
Version, Mack Publishing Company, Easton, Pa., 1990；And handbook of pharmaceutical excipients (Handbook
OfPharmaceutical Excipients), the second edition, 1994.
Further, the dosage form of the pharmaceutical preparation belongs to endo-medicine dosage form.
The endo-medicine dosage form of the present invention includes sugar coated tablet, film coated tablet, enteric coated tablet, capsule：Firmly
Capsule, soft capsule, oral solution, syrup, mouth containing agent, granule, electuary, pill, pill, powder, paste, sublimed preparation,
Suspension, pulvis, liquor, injection.
The production technology for preparing foregoing pharmaceutical preparation is well known to those skilled in the art.
According to a further aspect of the invention, the present invention also provides Chinese prescriptions to prepare treatment myasthenia gravis merging
Application in the drug of fash.
According to a further aspect of the invention, the present invention also provides foregoing herb liquids to prepare treatment severe flesh
Application in the powerless drug for merging fash.
Further, the myasthenia gravis merges fash and belongs to the severe with deficiency of both qi and yin, yin asthenia generating intrinsic heat, failure of skin and muscle to be nourished
Myasthenia merges fash.
The present invention is the special formulation arranged in pairs or groups meticulously according to the traditional theory " monarch " of Chinese medicine, by long-term clinic
Verification, effect have obtained clinical verification.
Specific implementation mode
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
All features disclosed in this specification or disclosed all methods or in the process the step of, in addition to mutually exclusive
Speciality and/or step other than, can combine in any way, unless specifically stated, can it is equivalent by other or have class
It is replaced like the alternative features of purpose, that is, unless specifically stated, one in a series of equivalent or similar characteristics of each feature
A embodiment.
The preparation of 1 herb liquid of embodiment
1, the following Chinese medicine material medicine of precise：10 parts of Radix Astragali, 10 parts of Radix Codonopsis, 10 parts of Rhizoma Atractylodis Macrocephalae, 5 parts of radix bupleuri, 5 parts of cimicifugae foetidae,
5 parts of Radix Angelicae Sinensis, 3 parts of Radix Glycyrrhizae, 3 parts of dried orange peel, 5 parts of matrimony vine, 9 parts of dogwood fruit, 10 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 6 parts of mulberries, 5 parts of the root of straight ladybell, waxgourd peel 5
Part, 5 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, 10 parts of radix pseudostellariae.
2, preparation method：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 5 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice；It boils medicine, is added total for the first time
The 2/3 of water, intense fire is suddenly fried boiling rise after change and be cooked by slow fire 20 minutes, pour out Chinese medicine concoction；The remaining dregs of a decoction are added surplus water and carry out
It boils medicine for the second time, same intense fire is suddenly decocted, and is cooked by slow fire after boiling 15 minutes, is poured out Chinese medicine concoction；
(3) hybrid filtering：It Chinese medicine concoction will be uniformly mixed twice, it is after cooling precipitation, upper layer liquid is medical by two layers
Gauze or the filtering of non-woven fabrics filter bag, obtain the herb liquid.
The preparation of 2 herb liquid of embodiment
1, the following Chinese medicine material medicine of precise：100 parts of Radix Astragali, 30 parts of Radix Codonopsis, 24 parts of Rhizoma Atractylodis Macrocephalae, 10 parts of radix bupleuri, cimicifugae foetidae 10
Part, 10 parts of Radix Angelicae Sinensis, 6 parts of Radix Glycyrrhizae, 6 parts of dried orange peel, 10 parts of matrimony vine, 12 parts of dogwood fruit, 24 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 15 parts of mulberries, 15 parts of the root of straight ladybell,
15 parts of waxgourd peel, 10 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, 20 parts of radix pseudostellariae.
2, preparation method：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 10 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice；It boils medicine, is added for the first time
The 2/3 of total Water, intense fire is suddenly fried boiling rise after change and be cooked by slow fire 25 minutes, pour out Chinese medicine concoction；The remaining dregs of a decoction be added surplus water into
Row is boiled medicine for the second time, and same intense fire is suddenly decocted, and is cooked by slow fire after boiling 20 minutes, is poured out Chinese medicine concoction；
(3) hybrid filtering：It Chinese medicine concoction will be uniformly mixed twice, it is after cooling precipitation, upper layer liquid is medical by two layers
Gauze or the filtering of non-woven fabrics filter bag, obtain the herb liquid.
The preparation of 3 herb liquid of embodiment
1, the following Chinese medicine material medicine of precise：50 parts of Radix Astragali, 20 parts of Radix Codonopsis, 15 parts of Rhizoma Atractylodis Macrocephalae, 8 parts of radix bupleuri, 8 parts of cimicifugae foetidae,
8 parts of Radix Angelicae Sinensis, 5 parts of Radix Glycyrrhizae, 5 parts of dried orange peel, 8 parts of matrimony vine, 10 parts of dogwood fruit, 15 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of mulberries, 10 parts of the root of straight ladybell, wax gourd
10 parts of skin, 8 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, 15 parts of radix pseudostellariae.
2, preparation method：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 8 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice；It boils medicine, is added total for the first time
The 2/3 of water, intense fire is suddenly fried boiling rise after change and be cooked by slow fire 20 minutes, pour out Chinese medicine concoction；The remaining dregs of a decoction are added surplus water and carry out
It boils medicine for the second time, same intense fire is suddenly decocted, and is cooked by slow fire after boiling 20 minutes, is poured out Chinese medicine concoction；
(3) hybrid filtering：It Chinese medicine concoction will be uniformly mixed twice, it is after cooling precipitation, upper layer liquid is medical by two layers
Gauze or the filtering of non-woven fabrics filter bag, obtain the herb liquid.
The effect of 4 oral solution of embodiment
1, the preparation of oral solution：
(1) herb liquid is prepared according to the method for embodiment 1- embodiments 3.
(2) herb liquid of step (1) is concentrated under reduced pressure into clear cream；
(3) 20% alcohol benzoate solution 6ml and 24% potassium sorbate solution 6ml is added, stirs evenly, refrigerates 48h or more, filter
It crosses, adds water to adjust to every milliliter and contain crude drug 5.5g, stir evenly, embedding is to get oral solution.
2, crowd is tested：Myasthenia gravis merges fash patient 80, is divided into three groups, takes the prescription according to embodiment 1
The patient group of the oral solution of preparation is known as 1 group, and the patient group for taking the oral solution of the prescription preparation according to embodiment 2 is known as 2 groups,
The patient group for taking the oral solution of the prescription preparation according to embodiment 3 is known as 3 groups.
3, therapy：It 100ml/ times, takes day 2 times, continuous Time of Administration 1 week.
4, efficacy assessment standard：
Effectively：Clinical symptoms disappearance has improvement；
In vain：Clinical symptoms are unchanged or aggravate.
5, efficacy result
Specific data ginseng is shown in Table 1.
1 efficacy result of table counts
The above content is a further detailed description of the present invention in conjunction with specific preferred embodiments, and it cannot be said that
The specific implementation of the present invention is confined to these explanations.For those of ordinary skill in the art to which the present invention belongs, exist
Under the premise of not departing from present inventive concept, a number of simple deductions or replacements can also be made, all shall be regarded as belonging to the present invention's
Protection domain.
Claims (10)
1. a kind of Chinese prescription treated myasthenia gravis and merge fash, which is characterized in that the Chinese prescription includes following heavy
Measure the bulk pharmaceutical chemicals of part：10-100 parts of Radix Astragali, 10-30 parts of Radix Codonopsis, 10-24 parts of Rhizoma Atractylodis Macrocephalae, 5-10 parts of radix bupleuri, 5-10 parts of cimicifugae foetidae, Radix Angelicae Sinensis
5-10 parts, 3-6 parts of Radix Glycyrrhizae, 3-6 parts of dried orange peel, 5-10 parts of matrimony vine, 9-12 parts of dogwood fruit, 10-24 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 6-15 parts of mulberries,
5-15 parts of the root of straight ladybell, 5-15 parts of waxgourd peel, 5-10 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, 10-20 parts of radix pseudostellariae.
2. Chinese prescription according to claim 1, which is characterized in that the Chinese prescription includes the raw material of following parts by weight
Medicine：50 parts of Radix Astragali, 20 parts of Radix Codonopsis, 15 parts of Rhizoma Atractylodis Macrocephalae, 8 parts of radix bupleuri, 8 parts of cimicifugae foetidae, 8 parts of Radix Angelicae Sinensis, 5 parts of Radix Glycyrrhizae, 5 parts of dried orange peel, matrimony vine 8
Part, 10 parts of dogwood fruit, 15 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of mulberries, 10 parts of the root of straight ladybell, 10 parts of waxgourd peel, 8 parts of Sagina subulata, 10 parts of rhizoma anemarrhenae, crown prince
15 parts of ginseng.
3. a kind of herb liquid treated myasthenia gravis and merge fash, which is characterized in that the herb liquid be by claim 1 or
2 Chinese prescription is obtained by the method that water decocts.
4. herb liquid according to claim 3, which is characterized in that the preparation method of the herb liquid is as follows：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 5-10 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice.
5. herb liquid according to claim 4, which is characterized in that the preparation method of the herb liquid is as follows：
(1) Chinese prescription bulk pharmaceutical chemicals polishing crushes, and is mixed into Chinese medicine powder；
(2) it is calculated according to 5-10 times of Chinese medicine powder weight and adds water inventory, boiled medicine at twice；It boils medicine, is added total for the first time
The 2/3 of water, intense fire is suddenly fried boiling rise after change and be cooked by slow fire 20-25 minutes, pour out Chinese medicine concoction；The remaining dregs of a decoction be added surplus water into
Row is boiled medicine for the second time, and same intense fire is suddenly decocted, and is cooked by slow fire after boiling 15-20 minutes, is poured out Chinese medicine concoction；
(3) hybrid filtering：It Chinese medicine concoction will be uniformly mixed twice, after cooling precipitation, upper layer liquid is passed through into two layers of hospital gauze
Or the filtering of non-woven fabrics filter bag, obtain the herb liquid.
6. a kind of pharmaceutical preparation treated myasthenia gravis and merge fash, which is characterized in that the pharmaceutical preparation is to want right
It asks and common auxiliary material in pharmacy is added after the Chinese medicinal liquid concentrating described in any one of 3-5 is prepared.
7. pharmaceutical preparation according to claim 6, which is characterized in that the dosage form of the pharmaceutical preparation belongs to medicine for oral administration agent
Type.
8. pharmaceutical preparation according to claim 7, which is characterized in that the endo-medicine dosage form includes sugar coated tablet, thin
Film coated tablet, enteric coated tablet, capsule：Hard capsule, soft capsule, oral solution, syrup, mouth containing agent, granule, punching
Agent, pill, pill, powder, paste, sublimed preparation, suspension, pulvis, liquor, injection.
9. application of the Chinese prescription as claimed in claim 1 or 2 in preparing treatment myasthenia gravis and merging the drug of fash.
10. the herb liquid described in any one of claim 3-5 is in preparing treatment myasthenia gravis and merging the drug of fash
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810769795.0A CN108524748B (en) | 2018-07-13 | 2018-07-13 | Traditional Chinese medicine composition for treating myasthenia gravis combined with rash |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810769795.0A CN108524748B (en) | 2018-07-13 | 2018-07-13 | Traditional Chinese medicine composition for treating myasthenia gravis combined with rash |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108524748A true CN108524748A (en) | 2018-09-14 |
| CN108524748B CN108524748B (en) | 2021-05-14 |
Family
ID=63488249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810769795.0A Active CN108524748B (en) | 2018-07-13 | 2018-07-13 | Traditional Chinese medicine composition for treating myasthenia gravis combined with rash |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108524748B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181967A (en) * | 1997-10-22 | 1998-05-20 | 薛廷民 | Shengguipeiyuan medicine granule for curing serious amyasthenia and its preparation |
| CN101537115A (en) * | 2008-03-19 | 2009-09-23 | 北京汉潮联创中药科技有限公司 | Chinese medicinal preparation for treating myasthenia gravis |
| CN103202976A (en) * | 2013-04-12 | 2013-07-17 | 贵阳中医学院第二附属医院 | Traditional Chinese medicine extract for treating myasthenia gravis and preparation method thereof |
| CN104069339A (en) * | 2014-06-18 | 2014-10-01 | 乞国艳 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof |
| CN104173853A (en) * | 2014-09-12 | 2014-12-03 | 中南林业科技大学 | Drug for treating ocular myasthenia gravis |
| CN105535448A (en) * | 2016-03-07 | 2016-05-04 | 乞国艳 | Traditional Chinese medicine composition for treating child myasthenia gravis |
-
2018
- 2018-07-13 CN CN201810769795.0A patent/CN108524748B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181967A (en) * | 1997-10-22 | 1998-05-20 | 薛廷民 | Shengguipeiyuan medicine granule for curing serious amyasthenia and its preparation |
| CN101537115A (en) * | 2008-03-19 | 2009-09-23 | 北京汉潮联创中药科技有限公司 | Chinese medicinal preparation for treating myasthenia gravis |
| CN103202976A (en) * | 2013-04-12 | 2013-07-17 | 贵阳中医学院第二附属医院 | Traditional Chinese medicine extract for treating myasthenia gravis and preparation method thereof |
| CN104069339A (en) * | 2014-06-18 | 2014-10-01 | 乞国艳 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof |
| CN104173853A (en) * | 2014-09-12 | 2014-12-03 | 中南林业科技大学 | Drug for treating ocular myasthenia gravis |
| CN105535448A (en) * | 2016-03-07 | 2016-05-04 | 乞国艳 | Traditional Chinese medicine composition for treating child myasthenia gravis |
Non-Patent Citations (1)
| Title |
|---|
| 刘建萌: "补中益气汤重用黄芪治疗重症肌无力25例临床观察", 《辽宁中医杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108524748B (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341004B (en) | Chinese medicine composition for treating delayed menstrual cycle | |
| AU2004204574A1 (en) | Herbal compositions for prostate conditions | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN104162057A (en) | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof | |
| CN101254261B (en) | Pharmaceutical combination with hypnogenesis, depression resistance and angst resistance effect and method of preparing the same | |
| CN104338043B (en) | A kind of medicine for improving immunity and preparation method thereof | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN101352514A (en) | Chinese medicinal composition for treating myasthenia gravis and preparation method thereof | |
| CN102488743B (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN102940785B (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN102429977B (en) | Medicine for treating diabetes | |
| CN101095768A (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN102526635A (en) | Medicament for treating premenstrual stress syndrome and preparation method thereof | |
| CN102416146B (en) | Chinese medicinal composition for treating amenorrhea | |
| CN108524748A (en) | Treat the Chinese medicine composition that myasthenia gravis merges fash | |
| CN103536815A (en) | Traditional Chinese medicinal composition for treating hemorrhoids symptoms | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN105106758A (en) | Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN104840891A (en) | Traditional Chinese medicine preparation used for treating alcoholic cardiomyopathy and preparation method thereof | |
| CN110368475A (en) | A kind of drug and preparation method thereof for malignant tumour early stage | |
| CN110420304A (en) | A kind of drug and preparation method thereof for the benign tumors sexual stage | |
| CN105250754B (en) | It is a kind of alleviate menopause symptom Chinese medicine composition and its application | |
| CN104162090B (en) | Pharmaceutical composition and preparation method thereof | |
| CN108653526B (en) | Traditional Chinese medicine formula for treating myasthenia gravis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |